We then validated our results of DAC-induced ICAM-1 upregulation in 6 additional patient-derived melanoma cell cultures (Figure 4d), regardless of the MAPK-sequence variant status or the resistance profile (please refer to Figure 6f for the treatments used). The gene discussed is ICAM1; the disease is melanoma.